Levetiracetam Mechanisms of Action: From Molecules to Systems
Open accessThe DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.
Abstract
Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In stress-sensitized and developmental perturbation paradigms, levetiracetam reverses anxiety-like, cognitive, and social deficits while rebalancing hippocampal and mesolimbic activity, consistent with network-level stabilization of prefrontal–hippocampal circuits [175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108 · cited 1×
“It is a chronic neurological disorder characterized by the presence of spontaneous and recurrent seizures caused by hyperactivity and the abnormal synchronization of neurons [2] that results in neuronal damage, inflammation, and the generation of reactive oxygen species”
BackgroundFisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483 · cited 1×
“According to the International League Against Epilepsy (ILAE), epileptic seizures are classified as focal-onset, generalized-onset, and unknown-onset seizures (previously known as partial and generalized seizures) [3].”
BackgroundTrinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 1×
“Status epilepticus (SE) is an emergency condition characterized by long-term seizures in which seizures lasting more than 30 min can be fatal [43]; benzodiazepines have been used as a first-line treatment for this condition.”
BackgroundThe role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“Currently, there is no doubt that LEV binds in a saturable, reversible, and stereospecific manner to SV2A in both rat and human brains; this is also true for its structural analogs [9,103].”
BackgroundGlia and epilepsy: excitability and inflammation
Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., & Rogawski, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.008 · Cited by 867
Buckley, K., & Kelly, R. B. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.4.1284 · Cited by 712
Pitkänen, A., & Sutula, T. P. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00073-x · Cited by 637 · cited 1×
“Antiepileptic drugs (AEDs; also named antiseizure drugs) efficiently control seizures, but only in about 2/3 of people with epilepsy [4]; moreover, during the last few years it has become clear that the current way of treating epilepsy with AEDs that only controls seizures is insufficient, since it does not cover the…”
BackgroundLevetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
Cereghino, J. J., Biton, V., Abou-Khalil, B., Dreifuss, F., Gauer, L. J., Leppik, I., & the United States Levetiracetam Study Group (2000) · Neurology · doi:10.1212/wnl.55.2.236 · Cited by 524
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Research works printed but not linked: 1
- Bonifacio S.L. Gonzalez F. Ferriero D.M. Chapter 61—Central Nervous System Injury and Neuroprotection Avery’s Diseases of the Newborn (Ninth Edition) Christine A.G. Devaskar S.U. W.B. Saunders Philadelpia, PA, USA 2012 869 891 978-1-4377-0134-0
Cited by
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Alshial, E. E., Abdulghaney, M. I., Wadan, A. S., Abdellatif, M. A., Ramadan, N. E., Suleiman, A. M., Waheed, N., Abdellatif, M., & Mohammed, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122257 · Cited by 98
Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay
Foiadelli, T., Santangelo, A., Costagliola, G., Costa, E., Scacciati, M., Riva, A., Volpedo, G., Smaldone, M. C., Bonuccelli, A., Clemente, A. M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1251914 · Cited by 91
de Castro, A. C., Nascimento, F. A., Beltrán‐Corbellini, Á., Toledano, R., García‐Morales, I., Gil‐Nagel, A., & Aledo‐Serrano, Á. (2023) · Seizure · doi:10.1016/j.seizure.2023.03.017 · Cited by 49
The AI Future of Emergency Medicine
Petrella, R. J. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.01.031 · Cited by 43
Current Issues in Pharmacy and Medical Sciences
(2024) · Current Issues in Pharmacy and Medical Sciences · doi:10.12923/j.2084-980x · Cited by 39
NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development
Haque, I., Thapa, P., Burns, D. M., Zhou, J., Sharma, M., Sharma, R., & Singh, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116078 · Cited by 35
“Due to the restrictive permeability and active efflux of some ASMs, including phenobarbital and phenytoin, the BBB limits the delivery and/or the transport of ASMs to the brain [116].”
BackgroundWaris, A., Siraj, M., Khan, A. A., Lin, J., Asim, M., & Alhumaydhi, F. A. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00494 · Cited by 34
Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A
Yamagata, A., Ito, K., Suzuki, T., Dohmae, N., Terada, T., & Shirouzu, M. (2024) · Nature Communications · doi:10.1038/s41467-024-47322-4 · Cited by 32
Amirshahrokhi, K., & Imani, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110165 · Cited by 24
Lin, C., Chang, M.-C., & Jhou, H. (2023) · CNS Drugs · doi:10.1007/s40263-023-01058-9 · Cited by 22
“In addition, the potential neuroprotective properties of levetiracetam may stem from the modulation of gamma-aminobutyric acid (GABA) and glutamate neurotransmitters during neuronal injury [40].”
Innate immune activation and neuroinflammatory pathways in Epilepsy
Solanki, P., & Jha, S. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.06.009 · Cited by 17
Designing drugs optimized for both blood–brain barrier permeation and intra-cerebral partition
Dichiara, M., Cosentino, G., Giordano, G., Pasquinucci, L., Marrazzo, A., Costanzo, G., & Amata, E. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2294118 · Cited by 15
“This drug – used to treat seizures – was observed to rapidly penetrate the BBB reaching the brain parenchyma [12], where it may act by binding to the synaptic vesicle protein 2A, which is involved in the release of neurotransmitters from nervous cells [13].”
BackgroundEpilepsy and autophagy modulators: a therapeutic split
Al-Kuraishy, H. M., Jabir, M. S., Al-Gareeb, A. I., Albuhadily, A. K., Klionsky, D. J., & Rafeeq, M. F. (2025) · Autophagy · doi:10.1080/15548627.2025.2506292 · Cited by 21
“The exact mechanism by which levetiracetam acts to treat epilepsy is unknown; it does not inhibit voltage-dependent Na + channels, GABAergic transmission, and glutamatergic receptors [190].”
Evaluation of the Antioxidant Activity of Levetiracetam in a Temporal Lobe Epilepsy Model
Ignacio‐Mejía, I., Contreras‐García, I. J., Mendoza‐Torreblanca, J. G., Medina‐Campos, O. N., Pedraza‐Chaverrí, J., García‐Cruz, M. E., Romo‐Mancillas, A., Gómez‐Manzo, S., Bandala, C., Sánchez‐Mendoza, M. E., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030848 · Cited by 15
“Furthermore, it has also shown anti-inflammatory, anti-ictogenic, and neuroprotective therapeutic properties [26].”
BackgroundSelf-citationPresynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“At the post-synaptic level, it modulates the AMPA receptors [57].”
BackgroundInfluentialSarangi, S. C., Pattnaik, S. S., Dash, Y., Tripathi, M., & Velpandian, T. (2024) · Seizure · doi:10.1016/j.seizure.2024.08.003 · Cited by 13
Gee, A., Dazzan, P., Grace, A. A., & Modinos, G. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03221-2 · Cited by 15
“Levetiracetam targets synaptic vesicle protein 2A and reduces pre-synaptic glutamate by regulating the expression/traf fi cking of synaptic vesicle sensor proteins and blocking voltage-gated calcium channels [206].”
Amirshahrokhi, K., & Imani, M. (2024) · Inflammation · doi:10.1007/s10753-024-02007-4 · Cited by 11
Koseki, T., Horie, M., Kumazawa, S., Nakabayashi, T., & Yamada, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1091386 · Cited by 10
Refinement of the pilocarpine-induced status epilepticus model in mice to improve mortality outcomes
Jiang, M., & Wang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1592014 · Cited by 9
Li, C., Wang, Z., Ren, M., Ren, S., Wu, G., & Wang, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14778 · Cited by 9
“4,5 SV2A expression was downregulated by 30% in the hippocampus and temporal cortex of patients with pharmacoresistant temporal lobe epilepsy with hippocampal sclerosis.”
BackgroundMansoor, A., Shahzad, M., Zulfiqar, E., Ahsan, M., Adnan, R., Shaeen, S. K., Banatwala, U. E. S. S., & Malikzai, A. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00462-x · Cited by 8
Overview of psychiatric and behavioral adverse effects of levetiracetam
Alkhotani, A. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1783559 · Cited by 7
Dinoi, G., Conte, E., Palumbo, O., Benvenuto, M., Coppola, M. A., Palumbo, P., Lastella, P., Boccanegra, B., Muro, E. D., Castori, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081698 · Cited by 9
Mohamadi, M. H., Bavafa, A., Salehi, S., Abedi, M., Shahabi, F., Jafarlou, S., Kolivand, P., & Negah, S. S. (2025) · Current Therapeutic Research · doi:10.1016/j.curtheres.2025.100798 · Cited by 8
Mittal, A., Martin, M. F., Provins, L., Hall, A., Ledecq, M., Wolff, C., Gillard, M., Horanyi, P. S., & Coleman, J. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2510239122 · Cited by 7
McKevitt, C., Marenco-Hillembrand, L., Bamimore, M. A., Chandler, R., Otamendi-Lopez, A., Almeida, J. P., Quiñones‐Hinojosa, A., & Chaichana, K. L. (2023) · Acta Neurochirurgica · doi:10.1007/s00701-023-05571-0 · Cited by 7
Cumbres-Vargas, I. M., Zamudio, S., Pichardo‐Macías, L. A., & Juan, E. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076488 · Cited by 6
“These promising agents include atorvastatin, ceftriaxone, topiramate (TOP) [20], levetiracetam [26], and thalidomide (TAL) [27] among others.”
BackgroundSelf-citationKoons, M., Koehl, J. L., Johnson, R., Rosenthal, E. S., & Webb, A. J. (2024) · Epilepsia · doi:10.1111/epi.18079 · Cited by 6
Panahi, Y., Fathi, E., & Shafiian, M. A. (2023) · Epilepsy Research · doi:10.1016/j.eplepsyres.2023.107206 · Cited by 6
Factors Affecting Sleep and Wakefulness in People with Epilepsy: A Narrative Review
Burkojus, D., Gelžinienė, G., Pajėdienė, E., Stankevičienė, G., Misevičienė, V., & Jurkevičienė, G. (2025) · Medicina · doi:10.3390/medicina61061000 · Cited by 6
“LEV is a second-generation ASM that acts as a synaptic vesicle protein 2A modulator, thus diminishing epileptogenesis [166].”
Analytical Biomarkers for Inflammation Status Monitoring of Psychotropic and Antiepileptic Drugs
Jiers, W., Sommerfeld-Klatta, K., Gümüştaş, M., Mozdziak, P. E., Łukasik‐Głębocka, M., Tężyk, A., Żaba, Z., Żaba, C., & Piotrowska‐Kempisty, H. (2025) · Pharmaceuticals · doi:10.3390/ph18081213 · Cited by 5
Montazerlotfelahi, H., Ketabforoush, A. H. M. E., Tavakol, M., Ashrafi, M. R., Dehghani, M., Mostafavi, K., Mardi, S., & Tajfirooz, S. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02954-7 · Cited by 5
Adjunctive treatment for pediatric focal epilepsy: a systematic review
Wang, S., Sun, H., Wang, Z., Sun, C., Zhang, X., & Liu, C. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03807-9 · Cited by 5
“LEV may inhibit epileptogenic by increasing SV2A inhibition [29].”
Ion Channels as Targets in Drug Discovery: Outlook and Perspectives
Stevens, E. B., & Stephens, G. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-52197-3_1 · Cited by 8
Shimazaki, H. (2025) · Genes · doi:10.3390/genes16030335 · Cited by 4
“However, levetiracetam has many actions, such as decreasing the function of SV2A, modulating synaptotagmin protein expression and traffic, reducing potassium currents, modulating GAD, increasing GABA transaminase, blocking GABA A receptors, and modulating AMPA receptors [17].”
Evaluation of Neuroinflammatory Contribution to Neurodegeneration in LRRK2 Drosophila Models
Nguyen, H. N., Galleri, G., Rassu, A. L., Ciampelli, C., Bernardoni, R., Galioto, M., Albani, D., Crosio, C., & Iaccarino, C. (2024) · Biomedicines · doi:10.3390/biomedicines12071555 · Cited by 4
Ignacio‐Mejía, I., Contreras‐García, I. J., Pichardo‐Macías, L. A., García‐Cruz, M. E., Ramírez‐Mendiola, B., Bandala, C., Medina‐Campos, O. N., Pedraza‐Chaverrí, J., Cárdenas‐Rodríguez, N., & Mendoza‐Torreblanca, J. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179313 · Cited by 4
“Chronic conditions likely induce the upregulation of endogenous antioxidant mechanisms as a compensatory response to sustained oxidative damage, and the role of LEV may shift from that of an enhancer to that of a stabilizer of this new redox state [73].”
BackgroundSelf-citationComparative analysis of brivaracetam and levetiracetam in epilepsy treatment
Hsu, M.-Y., Hu, S.-W., & Fan, H. (2025) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-24-00027 · Cited by 5
Levetiracetam: An antiseizure drug with unique neuroprotective properties
Ewens, A. N., & Thayer, S. A. (2025) · ASPET Discovery · doi:10.1016/j.aspetd.2025.100006 · Cited by 5
Díaz-Villegas, V., Pichardo‐Macías, L. A., Juárez‐Méndez, S., Ignacio‐Mejía, I., Cárdenas‐Rodríguez, N., Vargas-Hernández, M. A., Mendoza‐Torreblanca, J. G., & Zamudio, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031690 · Cited by 4
Self-citationFiais, G. A., Ferreira, D. S. D. B., de Freitas, R. N., da Silva, L. G. L., Kawaguchi, M., Veras, A. S. C., Teixeira, G. R., Antoniali, C., Dornelles, R. C. M., Nakamune, A. C. D. M. S., et al. (2023) · Toxicology · doi:10.1016/j.tox.2023.153615 · Cited by 4
Rauch, E., Ari, C., D’Agostino, D. P., & Kovács, Z. (2025) · Nutrients · doi:10.3390/nu17101721 · Cited by 3
“…excitatory and inhibitory neurotransmission, such as the glutamatergic and GABAergic systems, respectively, through alteration of the presynaptic release of glutamate (reducing) and GABA (increasing), leading to decrease in both hyperexcitability and, therefore, epileptic seizures [1,4,6,7].”
InfluentialFaysal, A. A., Şenel, P., Erdoğan, T., & Gölcü, A. (2025) · ChemistryOpen · doi:10.1002/open.202500191 · Cited by 3
Mohapatra, L., Mishra, D., Tripathi, A. S., Parida, S. K., & Palei, N. N. (2025) · Neuroglia · doi:10.3390/neuroglia6030026 · Cited by 3
“The observed antiepileptogenic and disease-modifying effects in animal studies typically manifest at doses that are clinically relevant, corresponding to clinically significant plasma concentrations [52].”
Huang, H., & Wang, C. (2025) · Neurology · doi:10.1212/wnl.0000000000214319 · Cited by 3
Santo, F. M., Schneider, H. U., Rosenstock, T., Moser, I., Denker, M., Vajkoczy, P., Picht, T., & Engelhardt, M. (2025) · Acta Neurochirurgica · doi:10.1007/s00701-025-06726-x · Cited by 3
Swierz, J., Doherty, M., Ji, S., Iliff, J. J., & Cho, Y. (2026) · Epilepsy Research · doi:10.1016/j.eplepsyres.2025.107730 · Cited by 3
Advances in the Synthesis of Levetiracetam: Classical Approaches and Patented Innovations
Sivaprakash, M., Tejaswini, K. B., Pulukuri, K. K., Gopinath, P., & Balaraman, E. (2026) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70358 · Cited by 4
Iqbal, S., Olivares, C. B., Rizzo, L., Parker, T. D., Wong, C., Underwood, B. R., Carpenter, J. R., Dunne, R. A., Raymont, V., Reith, A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71495 · Cited by 3
Ewens, A. N., Pilski, A., Hastings, S. D., Krook-Magnuson, C., Graves, S. M., Krook-Magnuson, E. I., & Thayer, S. A. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002272 · Cited by 3
Beschi, F., Hughes, R., & Schneider, J. (2024) · Pharmacy · doi:10.3390/pharmacy12040125 · Cited by 3
Anti-seizure medication prescription preferences: a Moroccan multicenter study
Naji, Y., Hrouch, W., Laadami, S., & Adali, N. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1435075 · Cited by 3
“He does not share affinity with the targets of other ASMs, such as VPA, PB, or Diazepine, and it may also have an interesting direct neuroprotective effect (34).”
BackgroundNajafi, S., Alavi, M. S., & Sadeghnia, H. R. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42244 · Cited by 3
“LEV is a novel broad-spectrum ASM that mainly interacts with the synaptic vesicle protein 2 A (SV2A), and regulates the balance of neurotransmitters in the brain, particularly those involved in regulating excitability and inhibition, reducing excess activity that can cause seizures [11 – 13].”
Exploring how levetiracetam mitigates toxicity and ameliorates memory impairment
Alhowail, A. H., & Alharbi, A. M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1651414 · Cited by 3
Kajevu, N., Lipponen, A., Andrade, P., Bañuelos‐Cabrera, I., Puhakka, N., Hämäläinen, E., Natunen, T., Hiltunen, M. O., & Pitkänen, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814049 · Cited by 3
García, E. H., Naranjo, L., Pichardo‐Macías, L. A., Bernad‐Bernad, M. J., Pastrana, L. I. C., Ruíz-Garcìa, M., Bernal, T. A. G., Solís, J. L. M., Guzmán, D. C., Díaz‐García, L., et al. (2023) · Children · doi:10.3390/children10111775 · Cited by 8
“…government-funded, teaching hospital that cares for pediatric patients with third-level pathologies coming from all over the country, conducting intensive pharmacovigilance studies such as ours is essential to begin to understand the safety and efficacy of medications in pediatric patients.”
BackgroundSelf-citationPostoperative Seizure Prophylaxis in Meningioma Resection: A Systematic Review and Meta-Analysis
Batista, S., Bertani, R., Palavani, L. B., Oliveira, L. D. B., Borges, P., Koester, S. W., & Paiva, W. S. (2023) · Diagnostics · doi:10.3390/diagnostics13223415 · Cited by 3
Aiswarya, N., Rahul, C. N., Kothandan, G., Kurup, M. R. P., Manoj, E., Chandrasekaran, P., Jeyakanthan, J., & Sekar, K. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137219 · Cited by 3
Efficacy and Safety of Levetiracetam for Childhood Epilepsies
Ćatibušić, F. H., Užičanin, S., Vukas, E., & Huseinbegovic, Z. (2024) · Medical Archives · doi:10.5455/medarh.2024.78.122-126 · Cited by 3
“It makes it useful in patients with hepatic dysfunction and it is independent of the hepatic cytochrome p450 (CYP450) system (3).”
BackgroundInfluentialEffect of levetiracetam on DNA oxidation and glutathione content in a temporal lobe epilepsy model
Contreras‐García, I. J., Bandala, C., Ignacio‐Mejía, I., Pichardo‐Macías, L. A., Mendoza‐Torreblanca, J. G., García‐Cruz, M. E., Gómez‐Manzo, S., & Cárdenas‐Rodríguez, N. (2024) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2024-2537 · Cited by 3
“However, LEV has been shown to have other therapeutic effects such as anti‑inflammatory, in the treatment of motor or cognitive disease, anticancer and anti‑ictiogenic ef‑ fects (Contreras‑García et al., 2022).”
BackgroundSelf-citationAydın, H., Aytaç, A., Bülbül, E., Yanık, B., Korkut, O., & Gülcen, B. (2024) · Medicina · doi:10.3390/medicina60081355 · Cited by 3
Levetiracetam for pediatric migraine prophylaxis: A narrative review
Shahrokhi, M., Pur, A. M. D. F., Shafaei-Bajestani, N., & Mashayekhi‐Sardoo, H. (2024) · Brain and Development · doi:10.1016/j.braindev.2024.104304 · Cited by 2
Therapeutic Advances in Drug-Resistant Epilepsy
Maynard, E. H. H., Ţînţ, D., González, J. G., & Chacón, L. M. M. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001836 · Cited by 2
Hoydonckx, Y., Feoktistov, A., Amoozegar, F., Anderson, C., Barad, M. J., Burke, E., Chitsantikul, P., Doshi, T. L., Englesakis, M. F., Goel, A., et al. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2025-106718 · Cited by 2
“91 Levetiracetam has a favorable pharmacokinetic profile with rapid and complete absorption following oral administration, excellent bioavailability, quick achievement of steady state concentrations, linear kinetics, and minimal plasma protein binding.”
Fan, L., Shen, Y., Zhang, J., Wang, X., Li, Y., Rao, X., Liu, H., Chen, J., Wang, J., Gong, X. Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11906-x · Cited by 3
“…demonstrates additional pharmacological effects involving the modulation of intracellular calcium signaling, GABAergic neurotransmission, and AMPA receptor-mediated excitatory pathways, and is known for its favorable pharmacokinetic properties, effectiveness, tolerability and safety profile 12 .”
Efficacy and safety of levetiracetam treatment in childhood epilepsy
TOKSÖZ, A., & Teber, S. (2025) · Turkish Journal of Pediatric Disease · doi:10.12956/tjpd.2025.1221 · Cited by 2
“Levetiracetam [(S)-α-ethyl-2-oxo-1-pyrrolidineacetamide] is a water-soluble pyrrolidine derivative and a new-generation antiepileptic drug introduced in 2000 (4).”
On Complexity and Emergence: Linking the Hypotheses of Pharmacoresistance in Epilepsy
Servilha‐Menezes, G., Talevi, A., & Garcia‐Cairasco, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-36526-3_4 · Cited by 2
Unpacking the psychological, cognitive, and psycho-pharmacologic burdens of neuro-oncology
Gatson, N. T., Szabo, R. J., Tadipatri, R., Lee, G. W., & Mach, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15663-2.00038-9 · Cited by 2
Parkinson's disease exacerbation following Levetiracetam administration: an unusual phenomenon
Alqahtani, L., Alkhaibary, A., & Bouhouf, F. (2025) · Oxford Medical Case Reports · doi:10.1093/omcr/omae174 · Cited by 2
Levetiracetam-induced seizure aggravation-case series and literature review
Friedman‐Korn, T., Benoliel, T., Doufish, D., Shifman, T. Y., Medvedovsky, M., & Ekstein, D. (2025) · Seizure · doi:10.1016/j.seizure.2025.04.005 · Cited by 3
“Since seizures were linked to both an increase and decrease in SV2A expression, there may be varying responses to LEV treatment [32], as has been demonstrated in two reports of seizure exacerbation following LEV in children with epilepsy discovered to be harboring SV2A mutations [11,12].”
Polet, S. S., de Koning, T. J., Lambrechts, R. A., Tijssen, M. A. J., Sibon, O. C. M., & Gorter, J. A. (2024) · Epilepsy Research · doi:10.1016/j.eplepsyres.2024.107380 · Cited by 2
HASEEB-UL-RASOOL, M., Elhawary, A., Saha, U., Sethi, A. K., Swaminathan, G., & Abosheaishaa, H. M. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04558-4 · Cited by 2
“…in prophylaxis against cyclic vomiting syndrome episodes, making it a potential treatment for a variety of pathologies; however, one of the known side effects of the medication itself is nausea and vomiting which make it less likely the reason for the improvement in the patients symptoms [27].”
BackgroundSurineni, K., Le, V., & Jones, D. (2024) · Cureus · doi:10.7759/cureus.62692 · Cited by 1
Hughes, S., Blumenthal, M., Johnson, A. M., Limjoco, J. J., & Lim, S. Y. (2025) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-30.2.170 · Cited by 1
Carrick, F. R., Daniels, P., Pelletier, S. R., Prysmakova, S., Hankir, A. K., Abdulrahman, M., & Alrumaihi, N. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080385 · Cited by 3
Stasevych, M., Hoidyk, M., Roman, O., Конечна, Р. Т., Karkhut, A., Lozynskyi, A., Polovkovych, S. V., & Lesyk, R. (2025) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2025.337842 · Cited by 1
A Effect of Antiepileptic Medication on Calcium Metabolism and BMD: A Cross-Sectional Study
Gupta, S., Sardana, V., Maheshwari, D., & Bhushan, B. (2024) · Journal of Modern Medicine · doi:10.4103/jomm.jomm_3_24 · Cited by 1
Pal, A., Singla, B., Singla, S., Rehman, M. H. U., Hamza, A., Mohammad, A., Abid, M., & Imran, A. (2025) · Cureus · doi:10.7759/cureus.91949 · Cited by 3
“…act by binding to synaptic vesicle glycoprotein 2A (SV2A), stabilizing neuronal firing and reducing excitatory neurotransmitter release, while benzodiazepines like diazepam enhance GABAergic (gamma-aminobutyric acid) inhibition, leading to broader central nervous system (CNS) suppression [23,24].”
Antiseizure medication effects on the autonomic nervous system in pediatric patients with epilepsy
Chafjiri, F. M. A., Dailey, S., Sadeghian, S., Ulate-Campos, A., & Loddenkemper, T. (2025) · Epilepsy Research · doi:10.1016/j.eplepsyres.2025.107688 · Cited by 3
Simon, E., Miklós, N., Frandeș, S.-D., Kolcsár, M., & Gáll, Z. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5040062 · Cited by 1
“Owing to its well-established efficacy and tolerability, levetiracetam (LEV) has progressively become a first-line treatment option for epilepsy over the years [9].”
Investigating the influence of anti-seizure medications on aperiodic EEG activity
Holden, M. M., Premoli, I., Clark, S. R., Richardson, M. P., Goldsworthy, M. R., & Rogasch, N. C. (2026) · Clinical Neurophysiology · doi:10.1016/j.clinph.2026.2112398 · Cited by 1
Lesion topography shapes motor thresholds in brain tumor patients
Stark, A., Goloshchapova, K., Spolaore, A., Gorbachuk, M., Gkampenis, A., Wang, S., Machetanz, K., Tatagiba, M., & Naros, G. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103924 · Cited by 1
Yan, L., Xie, L., Li, T., Chen, J., & Jiang, L. (2026) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2026.111228 · Cited by 1
Rychev, K. V., Pavlov, P. A., Кочетков, К. А., Gorunova, O. N., Bystrova, N. A., Oshchepkov, M., & Terent'ev, A. O. (2026) · Russian Chemical Reviews · doi:10.59761/rcr5233 · Cited by 1
Talevi, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-36526-3_20 · Cited by 1
Prakoso, Y. A., Hidayah, J. H., & Widyarini, S. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.188046 · Cited by 1
“The related mechanism between FC-C and piracetam as a nootropic drives there are no differences in the several biomarkers, including PWR and N/LR [44].”
BackgroundOn-demand seizures facilitate rapid screening of therapeutics for epilepsy
Chen, Y., Litt, B., Vitale, F., & Takano, H. (2026) · eLife · doi:10.7554/elife.101859.3 · Cited by 1
Bilateral Reversible Corneal Edema as a Novel Side-Effect of Levetiracetam – A Case Report
Caruana, K., Ellul, M., & Grixti, A. (2024) · International Medical Case Reports Journal · doi:10.2147/imcrj.s497262 · Cited by 1
Dybowski, F. P., Scott, D. S., & Tamminga, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02077-4 · Cited by 1
“We used this drug based on its HH-normalizing property in humans and hypothesized a similar effect, although possibly through a different mechanism of action [8, 72, 74, 96 – 101].”
Ardalani, G. F. (2025) · MNJ (Malang Neurology Journal) · doi:10.21776/ub.mnj.2025.011.01.23 · Cited by 1
Assessing adverse reactions in people living with epilepsy on levetiracetam
Ogunjimi, L., Osalusi, B. S., Alabi, A., Murtala, A. A., Irokosu, E. S., Aderinola, A. A., Aaron, U., Ogungbemi, D., Bolanle, F. O., ELEGBEDE, L., et al. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100273 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Tasya, G. A., Djatmiko, N. I., Rahman, F. H. F., & Rahmawati, V. K. (2023) · Medical Journal of Indonesia · doi:10.13181/mji.oa.236685
Dzul-Toledo, R. A., & González, N. C. (2023) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2023.5.1.7
Syntaxin1A overexpression and pain insensitivity in individuals with 7q11.23 duplication syndrome
Iadarola, M. J., Sapio, M. R., Loydpierson, A. J., Mervis, C. Β., Fehrenbacher, J. C., Vasko, M. R., Maric, D., Eisenberg, D. P., Nash, T. A., Kippenhan, J. S., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176147
Protective Effect of Rutin on Cognition Impairment Caused by Levetiracetam.
Upadhyay, S. D., Dwivedi, A., Mansoori, N., Goyal, P., & Jogi, J. (2024) · Journal of chemical health risks · doi:10.52783/jchr.v14.i01.3035
(2024) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2023-10233
Mónica Kyonen, L., Acuña, L., Ramos, B., Gutiérrez, J., & Barría, R. M. (2024) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2023-10233.eng
Maamouri, G., Boskabadi, H., Ashrafzadeh, F., Mehrad‐Majd, H., Miri, H. H., Kalani-Moghaddam, F., Nakhaei, M. H. A., & Rezapour, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4765436
Metadata
- Authors
- Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A.
- Affiliations
- Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, Ciudad de México 11200, Mexico
- Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico
- Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
- Secretaria de Salud (MX)
- Instituto Politécnico Nacional (MX)
- Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
- Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Ciudad de México 06720, Mexico
- Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-04-13
- Volume
- 15
- Issue
- 4
- Pages
- 475
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9030752
- OpenAlex
- W4223993843
- Cited by
- 131
- References
- 303
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 37 · 2023: 21
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- levetiracetam, antiepileptic drugs, epilepsy, seizure control, SV2A, calcium homeostasis, GABAergic system, AMPA receptors, multi-target drugs, drug repurposing, neuroprotection, anti-inflammatory activity, antioxidant activity, molecular targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.